Compare Quest Diagnostics Inc (DGX) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Marathon Petroleum Corp — how do they compare? Quest Diagnostics Inc trades at $203.96 (market cap $22.80B), while Marathon Petroleum Corp trades at $297.36 (market cap $88.57B). The key difference: Marathon Petroleum Corp is far larger — about 3.9× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | MPC | |
|---|---|---|
Market Cap | $22.80B | $88.57B |
Sector | Health | Energy |
52-Week High | $216.02 | $303.40 |
52-Week Low | $166.42 | $158.59 |
Enterprise Value | $28.82B | $120.75B |
Dividend Yield | 1.67% | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Marathon Petroleum (MPC) trades at $296.88, up 4.63% today and near its 52-week high. The stock shows strong momentum with bullish moving averages and a consensus analyst rating of Buy (75.76%). Recent earnings beat expectations in Q4 2025 and Q1 2026, though revenue has declined from $177.5B in 2022 to $132.7B in 2025. The company maintains solid profitability with a 3.42% net margin and 27.92% ROE, supported by a dividend payment of $1.00 scheduled for June 2026.
MPC's outlook is positive due to elevated refining margins and analyst optimism, but risks include volatile oil prices, legal challenges over AI pricing allegations, and declining revenue trends. The stock trades above the consensus price target of $292.70, suggesting limited near-term upside despite strong institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
